BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, one of a number of recent drugs developed for the treatment of CLL, targets Bruton’s tyrosine kinase (Btk), a signalling molecule that plays an essential role in B-cell development [66,69,70].